#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

ORLANDO, FL, USA (UroToday.com) - Presented by Chris Parker, Nicholas J. Vogelzang, A. Oliver Sartor, Robert E. Coleman, Fang Fang, Irene Skjorestad, and Sten Nilsson at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

gu cancers 2015 parker poster

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; Tulane Cancer Center, New Orleans, LA, USA; Weston Park Hospital, Sheffield, UK; Bayer HealthCare, Whippany, NJ, USA; Bayer AS (formerly Algeta ASA), Oslo, Norway; Karolinska University Hospital, Stockholm, Sweden

Click HERE to read related content